Hemostasis Disease States and Laboratory Determinations

A coagulation result becomes useful when the laboratory connects four questions: whether the clinical pattern suggests bleeding or thrombosis, whether the specimen is valid, which part of hemostasis the method measures, and which targeted assay can resolve the screening pattern. Serial change matters in consumptive disease. Reagent sensitivity matters in lupus anticoagulant and drug interference. A normal prothrombin time (PT) and activated partial thromboplastin time (APTT) still leave platelet, VWF, and factor XIII disorders in the differential.

Disease patterns

Acquired factor deficiency and dysfunction

Liver disease creates a rebalanced system: procoagulants and anticoagulants can fall together, while factor VIII and VWF may remain preserved or rise. PT and INR were calibrated for vitamin K antagonist monitoring and reflect only part of the bleeding-thrombosis balance in cirrhosis. A factor V result can support a distinction between severe hepatic synthetic failure and isolated vitamin K deficiency, but the whole clinical and laboratory pattern carries the interpretation.

Vitamin K deficiency follows poor absorption, biliary obstruction, limited intake with prolonged illness, or disruption of intestinal vitamin K supply. The short factor VII half-life makes PT the early screening change. A mixed deficiency involving II, VII, IX, and X supports the mechanism. Warfarin produces the same biochemical defect. Both conditions can transiently lower protein C and protein S, making congenital thrombophilia assessment uninterpretable during the deficiency.

Hereditary factor deficiencies

Hemophilia A is factor VIII deficiency and hemophilia B is factor IX deficiency. Both usually produce an isolated prolonged APTT, an immediate mixing correction, and reduced activity in the corresponding factor assay. Factor VIII circulates bound to VWF, so a low factor VIII result also prompts evaluation for VWD, especially type 2N or type 3. Women and girls with an F8 or F9 variant can have low factor activity and clinically important bleeding. The measured activity defines severity:¹

Factor XI deficiency is autosomal and produces a variable bleeding tendency that correlates poorly with activity. Contact-factor deficiencies, including factor XII, prekallikrein, and high-molecular-weight kininogen, can cause a striking APTT prolongation while clinical hemostasis stays intact.

A quantitative factor XIII activity assay is the preferred screen when the phenotype fits. Clot solubility tests detect only profound deficiency and can miss clinically important partial deficiency. One-stage factor assays can be influenced by APTT reagent, lupus anticoagulant, heparin, direct oral anticoagulants, and some factor replacement products. A chromogenic factor VIII or IX assay provides an alternate measurement principle when the one-stage result conflicts with the clinical or treatment setting.²

Inhibitors

A specific factor inhibitor and a lupus anticoagulant can both produce failure of a mixing study to correct, but their clinical and assay patterns differ.

• Specific factor VIII inhibitor. Acquired hemophilia A typically causes new bleeding, an isolated prolonged APTT, low factor VIII activity, and a time-dependent inhibitor pattern. Incubation can reveal inhibition after an immediate mix appeared to correct. A Nijmegen-Bethesda assay quantifies the inhibitor.
• Alloantibody in congenital hemophilia. Exposure to therapeutic factor can produce a neutralizing antibody. The laboratory reports inhibitor titer alongside factor activity and the treatment context.
• Lupus anticoagulant. An antiphospholipid antibody interferes with phospholipid-dependent clotting reactions. It produces an in-vitro inhibitor pattern and is clinically associated mainly with thrombosis or pregnancy morbidity. Rare lupus-hypoprothrombinemia can add bleeding through low prothrombin.
• Acquired VWF disorder. Accelerated clearance, adsorption to abnormal cells, shear-related loss of high-molecular-weight multimers, or an antibody can create a VWD-like panel with new-onset bleeding. Interpretation integrates the associated cardiac, lymphoid, myeloid, endocrine, or autoimmune disorder.

Thrombophilia and heparin-induced thrombocytopenia

Inherited thrombophilias include antithrombin, protein C, and protein S deficiency, factor V Leiden, and prothrombin G20210A. Acquired risks include antiphospholipid antibodies, cancer, pregnancy, estrogen exposure, immobility, surgery, inflammation, myeloproliferative neoplasms, and paroxysmal nocturnal hemoglobinuria. A broad inherited panel is rarely useful during an acute event or active anticoagulation. The 2023 American Society of Hematology guideline favors testing only in selected situations where the result would change a management decision; it advises against routine testing for many common VTE presentations.³

Common MTHFR polymorphisms are excluded from inherited thrombophilia panels because they lack diagnostic validity for inherited thrombophilia. Factor V Leiden directly alters the activated protein C cleavage site in factor V. Prothrombin G20210A is a 3′ untranslated-region variant associated with increased prothrombin; direct genotyping is the laboratory method because routine activity has inadequate discrimination.

Heparin-induced thrombocytopenia (HIT). IgG antibodies against platelet factor 4-heparin complexes can activate platelets through Fc receptors and produce thrombocytopenia with a strong thrombotic risk. The platelet fall commonly begins 5 to 10 days after a new exposure and may occur sooner after recent exposure. Laboratory testing follows clinical pretest probability. With an intermediate or high 4Ts score, test first with a PF4-heparin immunoassay. A positive immunoassay detects binding antibody; functional testing shows whether that antibody activates donor platelets in a heparin-dependent pattern. A low 4Ts score generally ends the laboratory pathway because false-positive antibody results can create a harmful diagnosis.⁴

Disseminated intravascular coagulation

Disseminated intravascular coagulation (DIC) is systemic coagulation activation caused by an underlying disorder. Thrombin generation, fibrin deposition, platelet and factor consumption, and secondary fibrinolysis occur together. Sepsis, major tissue injury or trauma, obstetric catastrophe, malignancy, severe transfusion reaction, and selected toxins are typical triggers. Schistocytes may appear as fibrin strands shear erythrocytes in small vessels.

The pattern is dynamic. Platelets fall, PT prolongs, D-dimer rises, and fibrinogen may fall. Early fibrinogen can remain within the interval or rise through the acute-phase response, so serial direction is more informative than one value. Chronic or compensated DIC can show mild or intermittent changes. A compatible trigger is required before a DIC score is applied.

The 2025 ISTH SSC update assigns points using each laboratory’s D-dimer upper limit of normal (ULN):⁵

A total of 5 or more is compatible with overt DIC in the proper setting. A lower score can represent early evolving disease and calls for serial reassessment. Liver disease can resemble DIC; a new consumptive trend, a credible trigger, and the full clinical pattern carry more weight than one factor result.

Coagulation specimens and instruments

Citrated plasma

Plasma clotting assays use blood collected into buffered 3.2% sodium citrate, 0.105 to 0.109 mol/L, at a 9:1 blood-to-anticoagulant ratio. The tube must fill to its validated volume and be mixed promptly and gently. Clots, wrong anticoagulant, substantial underfill, and collection contamination can make the result unusable. Current collection, transport, processing, storage, and rejection guidance is in CLSI H21, 6th edition.⁶

High hematocrit adjustment. At a hematocrit above 55%, plasma volume is reduced and a standard tube contains excess citrate for that plasma. Excess citrate binds part of the calcium added by the assay and falsely prolongs clotting times. One form of the adjustment for a tube’s intended total volume is:

Citrate volume (mL) = [(100 - hematocrit %) / (595 - hematocrit %)] × intended total tube volume (mL)

For an intended 4.5-mL collection at hematocrit 62%:

[(100 - 62) / (595 - 62)] × 4.5 = (38 / 533) × 4.5 = 0.32 mL citrate

The modified tube must be prepared and labeled under a validated laboratory procedure. The remaining volume is filled with blood to the intended total.

Prepare platelet-poor plasma under the assay’s validated centrifugation procedure. Residual platelets supply phospholipid, release platelet factor 4, and can distort heparin-sensitive and lupus anticoagulant studies. Plasma intended for freezing or lupus anticoagulant testing may require a second centrifugation step and a verified residual platelet limit. Follow assay-specific stability and frozen storage limits. Hemolysis, icterus, and lipemia can interfere with optical detection; mechanical clot detection or an analyzer’s validated interference correction can provide an alternate route.

End-point detection

• Mechanical detection senses the physical formation of fibrin by movement of a ball, probe, or electromechanical system and is less vulnerable to specimen color.
• Photo-optical detection follows the increase in turbidity as fibrin forms.
• Chromogenic detection measures color released when an enzyme cleaves a synthetic substrate. A direct assay produces more color with more analyte activity. An inhibitory assay, such as heparin anti-Xa, produces less color as analyte activity rises.
• Immunologic detection measures antigen-antibody binding by turbidity, nephelometry, fluorescence, or another validated signal and is common in D-dimer assays.
• Viscoelastic detection follows whole-blood clot initiation, strength, and lysis over time.

Screening tests and mixing studies

PT and INR

PT reagent supplies tissue factor, phospholipid, and calcium to citrated plasma. The result depends on factor VII and the common-pathway factors X, V, II, and fibrinogen. Vitamin K deficiency, warfarin, liver disease, DIC, factor deficiency, and some drugs can prolong it. Factors VIII, IX, XI, XII, and XIII lie outside its measured reaction.

Each laboratory verifies a reference interval for its reagent and instrument. For vitamin K antagonist monitoring, the international normalized ratio (INR) corrects much of the difference in thromboplastin sensitivity:

INR = (patient PT / mean normal PT)^ISI

The international sensitivity index (ISI) belongs to the reagent-instrument system. Local verification or calibration supports comparable reporting. INR has a defined role in vitamin K antagonist monitoring; applying it to liver disease or a direct oral anticoagulant creates a different and unvalidated meaning. Current one-stage PT and APTT procedure guidance is in CLSI H47, 3rd edition.⁷

APTT

APTT reagent supplies a contact activator and phospholipid; recalcification starts clot formation. The assay measures contact factors, XI, IX, VIII, and the common pathway. An isolated prolonged APTT can reflect hemophilia, factor XI or contact-factor deficiency, a specific inhibitor, lupus anticoagulant, unfractionated heparin, a direct thrombin inhibitor, or preanalytic contamination. Reagent composition changes sensitivity to lupus anticoagulant, heparin, and individual factor reductions. A normal APTT therefore cannot exclude every mild deficiency or drug effect.

Unfractionated heparin can be monitored with APTT when the laboratory has established a reagent- and instrument-specific therapeutic interval correlated with an accepted heparin measurement. Acute-phase factor VIII elevation can shorten APTT and obscure the heparin effect; lupus anticoagulant can prolong it independently. A chromogenic anti-Xa assay avoids these particular clot-time effects but has its own optical and drug interferences.

Mixing studies

A mixing study combines patient plasma 1:1 with pooled normal plasma and repeats the prolonged assay. Normal plasma supplies approximately half-normal activity for a missing factor. An inhibitor acts on the patient’s and pooled factor or on the assay phospholipid.

1. Review specimen integrity and the medication record. Thrombin time, anti-Xa, or a drug-specific assay can identify heparin or a direct anticoagulant before mixing.
2. Test the patient plasma, pooled normal plasma, and immediate 1:1 mix under the same conditions.
3. Interpret correction with a locally validated criterion, such as a mixing-test reference interval or an index of circulating anticoagulant. A corrected mix supports deficiency; persistent prolongation supports inhibitor or drug effect.
4. When a time-dependent factor VIII inhibitor remains possible, incubate patient plasma and the mix at 37 °C for the validated interval, commonly 2 hours, and retest with an incubated control.
5. Resolve the pattern with factor activity, lupus anticoagulant, inhibitor titer, or drug testing.

Strong lupus anticoagulants can show partial correction after dilution, and multiple factor deficiencies can show incomplete correction. Mixing is a classification step within an algorithm.

Thrombin time, reptilase time, and heparin neutralization

Thrombin time adds thrombin directly to plasma and measures fibrinogen conversion to fibrin. It is sensitive to low or dysfunctional fibrinogen, heparin, dabigatran and other direct thrombin inhibitors, and high concentrations of fibrin degradation products. A normal thrombin time makes a clinically important dabigatran concentration unlikely when the reagent is sufficiently sensitive.

Reptilase time uses a thrombin-like snake venom enzyme that cleaves fibrinopeptide A and is insensitive to heparin. Parallel prolongation of thrombin and reptilase times supports a fibrinogen quantity or function problem. A prolonged thrombin time with a normal reptilase time supports heparin or a direct thrombin inhibitor. A validated heparinase or polybrene neutralization procedure can confirm heparin interference when correction follows treatment.

Fibrinogen and fibrin turnover

Clauss fibrinogen

The Clauss method dilutes plasma, adds a high thrombin concentration, and converts clotting time to functional fibrinogen using a calibration curve. Clot time is inversely related to fibrinogen within the method’s reportable interval. A PT-derived fibrinogen estimate comes from the optical PT curve and may diverge at concentration extremes or in dysfibrinogenemia. Comparing functional fibrinogen with fibrinogen antigen helps identify a qualitative defect.

D-dimer

D-dimer assays use antibodies against products released from cross-linked fibrin. They document that thrombin formed fibrin, factor XIIIa cross-linked it, and plasmin later digested it. Inflammation, pregnancy, surgery, trauma, cancer, and increasing age can all raise the result. Within a validated clinical algorithm, a result below the assay cutoff can exclude acute venous thromboembolism in a patient with low or selected intermediate pretest probability. A positive result has broad causes.

Manufacturers report either fibrinogen-equivalent units (FEU) or D-dimer units (DDU). FEU values are often roughly twice DDU values, yet assay antibodies and calibrators vary. Interpret the exact unit, assay, and cutoff supplied by the laboratory. The updated DIC score likewise uses multiples of the assay’s own ULN.

Platelet and VWF testing

Platelet function

A platelet function analyzer draws citrated whole blood through a collagen-and-agonist-coated aperture under high shear and reports closure time. VWF, platelet count, hematocrit, medication exposure, and preanalytic delay all influence the result. It is a screening adjunct with limited sensitivity for mild VWD and platelet defects.

Light-transmission aggregometry stirs platelet-rich plasma and records rising light transmission as platelets aggregate. Whole-blood impedance aggregometry records increasing electrical resistance as platelets coat electrodes. Lumiaggregometry measures ATP release at the same time, exposing a dense- granule secretion defect.

The existing Qualitative Platelet Defects module owns the diagnostic response patterns for Glanzmann thrombasthenia, Bernard-Soulier syndrome, and storage-pool disease.

VWF panel

Initial VWD testing combines VWF antigen, platelet-dependent VWF activity, and factor VIII activity. Newer GPIb-based activity assays have better precision and low-level performance than the traditional ristocetin cofactor assay. An activity-to-antigen ratio below 0.7 supports a qualitative type 2 pattern. Multimer analysis or collagen-binding activity evaluates high-molecular-weight forms; VWF-factor VIII binding or targeted genetics resolves suspected type 2N; targeted genetics is preferred for suspected type 2B in the 2021 guideline.⁸

VWF rises during inflammation, stress, pregnancy, and estrogen exposure. Test near baseline health when feasible and interpret with the local interval. The Qualitative Platelet Defects module owns the VWD disease types and diagnostic thresholds; this panel description defines what each laboratory measurement contributes.

Factor and inhibitor assays

A one-stage factor assay mixes serial patient-plasma dilutions with plasma lacking the factor of interest and measures PT or APTT. Correction is compared with a reference-plasma calibration curve. PT-based assays measure II, V, VII, and X. APTT-based assays measure VIII, IX, XI, and XII. Dilution linearity can reveal an inhibitor, lupus anticoagulant, or drug effect. Chromogenic factor assays measure enzyme generation through a synthetic substrate and provide a useful alternate principle for factor VIII or IX.

The Nijmegen-Bethesda assay quantifies a factor VIII inhibitor. Buffered normal plasma is mixed with serial patient-plasma dilutions and incubated for 2 hours at 37 °C; residual factor VIII is measured. One Bethesda unit is the inhibitor amount that leaves 50% residual factor VIII under the stated conditions. The reciprocal of the dilution giving 50% residual activity determines the titer. Recent factor replacement or a non-factor therapy can require specialized specimen preparation and assay selection.

Lupus anticoagulant and thrombophilia assays

Lupus anticoagulant testing uses two phospholipid-dependent systems with different principles, usually dilute Russell viper venom time (dRVVT) and an LA-sensitive APTT such as a silica clotting time. Each system evaluates screen, mix, and phospholipid-rich confirm results. A normalized confirmatory ratio showing shorter clotting with excess phospholipid supports phospholipid dependence. Factor deficiency, specific inhibitors, heparin, vitamin K antagonists, and direct oral anticoagulants must be resolved before the laboratory assigns an LA interpretation. Cutoffs are reagent- and population-specific.⁹

Anticardiolipin IgG/IgM and anti-β2-glycoprotein I IgG/IgM are solid-phase immunoassays and complete the antiphospholipid laboratory profile. Persistent positivity requires repeat demonstration at least 12 weeks later for antiphospholipid syndrome classification. The report names the assay, units, cutoff, and anticoagulant limitations.

Antithrombin activity is commonly measured by inhibition of added Xa or thrombin. Protein C activity uses chromogenic or clot-based measurement after activation. Protein S testing separates free antigen, total antigen, and clot-based activity. Acute thrombosis, liver disease, DIC, pregnancy, estrogen, warfarin, heparin, nephrotic loss, and direct anticoagulants can alter one or more results. A possible congenital deficiency requires confirmation after acquired influences resolve and may require antigen classification or genetics.

An activated protein C resistance assay detects the factor V phenotype, and direct genotyping confirms factor V Leiden and zygosity. Direct genotyping also identifies prothrombin G20210A. Genetic results remain stable during anticoagulation and acute illness, although test selection still depends on whether the result will change care.

HIT functional testing

PF4-heparin immunoassays range from broad, highly sensitive enzyme immunoassays to rapid methods with different specificity. Optical density or signal strength contributes to post-test probability. A functional assay such as the serotonin-release assay or heparin-induced platelet activation assay incubates patient serum with donor platelets at low and high heparin concentrations. True HIT antibody activates platelets at the low therapeutic concentration; excess heparin disrupts the antigen complex and suppresses activation. Donor reactivity, assay expertise, and specimen timing influence sensitivity. Report the result with the clinical score and immunoassay strength.

Viscoelastic and thrombin-generation assays

Thromboelastography and rotational thromboelastometry test citrated or fresh whole blood as a clot forms and lyses. Their tracings describe initiation time, clot-building kinetics, maximum strength, and lysis. Platelets and fibrinogen both contribute to clot strength, and method-specific channels can separate their contributions or expose heparin effect. These assays support targeted assessment in trauma, cardiac surgery, liver transplantation, and other validated protocols. Endothelial function and many VWF or platelet defects lie outside their reliable sensitivity.

A thrombin-generation assay records lag time, peak thrombin, time to peak, and total endogenous thrombin potential. It captures more of the reaction than the first-fibrin endpoint of PT or APTT. Standardization and clinical decision limits remain assay- and setting-specific.

Anticoagulant measurement

Heparins and fondaparinux

The chromogenic anti-Xa assay adds a known amount of Xa to patient plasma. Heparin-accelerated antithrombin neutralizes part of it; residual Xa cleaves a chromogenic substrate. More heparin yields less color. Some reagents add antithrombin, while others depend on the patient’s antithrombin. The calibrator must match unfractionated heparin, low-molecular-weight heparin, or fondaparinux.

Unfractionated heparin can be monitored by a locally calibrated APTT or heparin anti-Xa assay. Low-molecular-weight heparin and fondaparinux usually require no routine laboratory monitoring. Selected protocols use a drug-calibrated anti-Xa result collected at a defined post-dose time. A direct Xa inhibitor can falsely elevate a heparin anti-Xa result, and hemolysis, icterus, lipemia, or low antithrombin can affect some methods.

Direct oral anticoagulants

Routine PT and APTT provide variable, reagent-dependent responses to direct oral anticoagulants and cannot quantify concentration. A normal PT can coexist with a clinically relevant apixaban level. A normal APTT can coexist with a low or moderate dabigatran level. Drug-specific assays provide the reliable measurement when testing is clinically indicated:¹⁰

Collection time relative to the last dose, renal function, dose, and assay calibration belong with the result. Direct oral anticoagulants can distort PT, APTT, mixing, factor activity, protein C or S activity, activated protein C resistance, and lupus anticoagulant assays. Collection after adequate drug clearance, measurement of the drug, or a validated adsorbent procedure can restore an interpretable pathway.

Intravenous direct thrombin inhibitors

Argatroban and bivalirudin are commonly followed with APTT under a drug- and protocol-specific target; activated clotting time is used for selected high-dose procedural settings. Both can prolong PT and INR. During overlap with warfarin, argatroban especially raises INR through assay effect. The laboratory and clinical protocol must account for that combined effect before interpreting the vitamin K antagonist contribution.

References

1. Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(suppl 6):1-158. doi:10.1111/hae.14046.
2. Keohane EM, Preston MM, Mirza KM, Walenga JM, eds. Rodak's Hematology: Clinical Principles and Applications. 7th ed. Elsevier; 2025. Accessed August 31, 2026.
3. Middeldorp S, Nieuwlaat R, Baumann Kreuziger L, et al. American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing. Blood Adv. 2023;7(22):7101-7118. doi:10.1182/bloodadvances.2023010177.
4. Cuker A, Arepally GM, Chong BH, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018;2(22):3360-3392. doi:10.1182/bloodadvances.2018024489.
5. Iba T, Levy JH, Maier CL, et al. Updated definition and scoring of disseminated intravascular coagulation in 2025: communication from the ISTH SSC Subcommittee on Disseminated Intravascular Coagulation. J Thromb Haemost. 2025;23(7):2356-2362. doi:10.1016/j.jtha.2025.03.038.
6. Clinical and Laboratory Standards Institute. Collection, Transport, and Processing of Blood Specimens for Testing Plasma-Based Coagulation Assays. 6th ed. CLSI standard H21. Clinical and Laboratory Standards Institute; 2024. Accessed August 31, 2026.
7. Clinical and Laboratory Standards Institute. One-Stage Prothrombin Time (PT) Test and Activated Partial Thromboplastin Time (APTT) Test. 3rd ed. CLSI standard H47. Clinical and Laboratory Standards Institute; 2023. Accessed August 31, 2026.
8. James PD, Connell NT, Ameer B, et al. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv. 2021;5(1):280-300. doi:10.1182/bloodadvances.2020003265.
9. Devreese KMJ, de Groot PG, de Laat B, et al. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation. J Thromb Haemost. 2020;18(11):2828-2839. doi:10.1111/jth.15047.
10. Douxfils J, Adcock DM, Bates SM, et al. 2021 update of the International Council for Standardization in Haematology recommendations for laboratory measurement of direct oral anticoagulants. Thromb Haemost. 2021;121(8):1008-1020. doi:10.1055/a-1450-8178.